Genzyme

Genzyme backs Osiris, despite Prochymal flop

Nature (Free subscription) | 06/11/2009

Genzyme backs Osiris, despite Prochymal flop Nature Biotechnology 27, 966 (2009). doi:10.1038/nbt1109-966 Author: Malorye Allison

Modfied HIV Delivered Gene Therapy Could Treat Many Diseases

advanced nanotechnology (Free subscription) | 06/11/2009

In a pilot study of two patients monitored for two years, an international team of researchers slowed the onset of the debilitating brain disease X-linked adrenoleukodystrophy (ALD) using a lentiviral vector to introduce a therapeutic gene into patient's blood cells. Although studies with larger cohorts of patients are needed, these results suggest that gene therapy with lentiviral vectors, which...

EXACT Sciences (NASDAQ: EXAS): Patience Required For Long-Term Upside

iStockAnalyst.com (Free subscription) | 05/11/2009

On 11/3/09, EXACT Sciences (NASDAQ: EXAS) reported its 3Q09 results and held a conference call to outline the Company's progress and timeline for the development of a stool DNA based test kit for the early diagnosis and prevention of colorectal cancer (CRC). EXAS reported total revenue of $1.3 million (which primarily reflects non-cash recognition of Genzyme deal earlier this year), a net loss of $1...

Zacks Bull and Bear of the Day Highlights: McDonald's, Genzyme, Berkshire Hathaway, Burlington Northern Santa Fe Corp and Berkshire Hathaway

The Earth Times Online Newspaper (Free subscription) | 04/11/2009

CHICAGO - Zacks Equity Research highlights McDonald's (NYSE:

Zacks Bull and Bear of the Day Highlights: McDonald's, Genzyme, Berkshire Hathaway, Burlington Northern Santa Fe Corp and Berkshire Hathaway

Business Wire (Free subscription) | 04/11/2009

CHICAGO--(BUSINESS WIRE)--Zacks Equity Research highlights McDonald's (NYSE: MCD) as the Bull of the Day and Genzyme (Nasdaq: GENZ) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Berkshire Hathaway (NYSE: BRK.A), Burlington Northern Santa Fe Corp (NYSE: BNI) and Berkshire Hathaway (NYSE: BRK.B). Full analysis of all these stocks is available at http://at.zacks.com/?id=2678....

Genzyme plant gets OK from European regulators

bizjournals (Free subscription) | 03/11/2009

Genzyme Corp. said Tuesday that European regulators have given the company’s troubled Allston, Mass.-based plant the OK to manufacture medications for European patients.

• Genzyme plant gets OK from European regulators - The Boston Business Journal

Framingham Sewer Project In Full Flow

WBJournal.com (Free subscription) | 03/11/2009

It may be a time of state budget cuts and stalled private development, but in Framingham both the public and private sectors are moving forward on a major biomanufacturing project. The Massachusetts Life Sciences Center recently announced that it is providing $7.7 million to help the town fund an expansion of the sewer system that is intended primarily to support the new biomanufacturing facility that...

Report: Pfizer may make a bid for Protalix

Fiercebiotech (Free subscription) | 02/11/2009

Israel's Protalix BioTherapeutics ( PLX ) has seen its shares skyrocket 415 percent this year. And its success developing a new Gaucher disease therapy appears to have attracted some intense interest from Pfizer. Reporters at TheMarker say that a delegation from Pfizer visited Protalix's facilities in Israel in anticipation of a development deal and possible buyout. Protalix Chief Executive David...

ScreenScape appoints Rob Binns Chief Financial Officer

PR News Wire (Free subscription) | 29/10/2009

OAKVILLE, ON and CHARLOTTETOWN, PE, Oct. 29 /PRNewswire/ - ScreenScape Networks Inc., the leader in Venue Networking, today announced that it has appointed Rob Binns, CA as its Chief Financial Officer (CFO). An alumnus of Acadia University, Binns brings with him 15 years experience in executive management, financial planning, and budget management functions, having held senior level positions at Genzyme,...

Marsha Fanucci Joins Ironwood Board of Directors

PR News Wire (Free subscription) | 27/10/2009

CAMBRIDGE, Mass., Oct. 27 /PRNewswire/ -- Ironwood Pharmaceuticals, Inc. today announced that Marsha Fanucci has joined its Board of Directors. Ms. Fanucci served at Millennium Pharmaceuticals, Inc. from 2000-2009 in a number of senior positions, including chief financial officer and senior vice president of strategy, vice president of finance and strategy, and vice president of corporate development...

Zacks Sell List Highlights: Pinnacle Financial Partners, Marten Transport Ltd., Genzyme Corporation and MDS Inc.

Business Wire (Free subscription) | 23/10/2009

CHICAGO--(BUSINESS WIRE)--Zacks.com releases details on a group of stocks that are currently members of the exclusive Zacks #5 Rank List – Stocks to Sell Now. These stocks are currently rated as a Zacks Rank #5 (Strong Sell): Pinnacle Financial Partners (Nasdaq: PNFP) and Marten Transport Ltd. (Nasdaq: MRTN). Further, Zacks announced #4 Rankings (Sell) on two other widely held stocks: Genzyme...

Zacks Analyst Blog Highlights: US Bancorp, Visa Inc., Genzyme Corp, Shire plc and Protalix BioTherapeutics Inc.

The Earth Times Online Newspaper (Free subscription) | 22/10/2009

CHICAGO - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: US Bancorp (NYSE:

Zacks Analyst Blog Highlights: US Bancorp, Visa Inc., Genzyme Corp, Shire plc and Protalix BioTherapeutics Inc.

Business Wire (Free subscription) | 22/10/2009

CHICAGO--(BUSINESS WIRE)--Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: US Bancorp (NYSE: USB), Visa Inc. (NYSE: V), Genzyme Corp (Nasdaq: GENZ), Shire plc (Nasdaq: SHPGY) and Protalix BioTherapeutics Inc. (NYSE:...

The Gift That Keeps on Giving

Fool.com (Free subscription) | 22/10/2009

Manufacturing problems knock down Genzyme.

First Patient Enrolled In Phase 3 Trials Of Genzyme Oral Capsule For Gaucher Disease

Medical News Today (Free subscription) | 22/10/2009

Genzyme Corporation (NASDAQ: GENZ) announced that the company has begun enrollment in the first of two global, multi-center, phase 3 trials of Genz-112638, a potential new oral therapy for Gaucher disease type 1. The two multi-national, multi-center trials are being conducted to evaluate the safety and efficacy of the small molecule.